Tower Research Capital (TRC)’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,051
| Closed | -$4.81K | – | 5561 |
|
|
2025
Q3 | $4.81K | Sell |
1,051
-414
| -28% | -$1.84K | ﹤0.01% | 4293 |
|
|
2025
Q2 | $1.82K | Sell |
1,465
-1,122
| -43% | -$1.4K | ﹤0.01% | 4740 |
|
|
2025
Q1 | $3.47K | Sell |
2,587
-3,513
| -58% | -$5.4K | ﹤0.01% | 4405 |
|
|
2024
Q4 | $8.91K | Buy |
6,100
+5,722
| +1,514% | +$20K | ﹤0.01% | 3955 |
|
|
2024
Q3 | $2.53K | Sell |
378
-518
| -58% | -$3.41K | ﹤0.01% | 4981 |
|
|
2024
Q2 | $6.73K | Buy |
896
+556
| +164% | +$7.5K | ﹤0.01% | 4549 |
|
|
2024
Q1 | $5.07K | Buy |
340
+78
| +30% | +$1.05K | ﹤0.01% | 4589 |
|
|
2023
Q4 | $3.64K | Buy |
+262
| New | +$3.56K | ﹤0.01% | 5054 |
|
|
2023
Q3 | – | Sell |
-64
| Closed | -$5.53K | – | 6204 |
|
|
2023
Q2 | $5.53K | Buy |
64
+34
| +113% | +$2.4K | ﹤0.01% | 4820 |
|
|
2023
Q1 | $2K | Sell |
30
-23
| -43% | -$3.72K | ﹤0.01% | 5396 |
|
|
2022
Q4 | $11K | Buy |
53
+29
| +121% | +$6.35K | ﹤0.01% | 3867 |
|
|
2022
Q3 | $6K | Buy |
24
+20
| +500% | +$11.7K | ﹤0.01% | 5050 |
|
|
2022
Q2 | $3K | Buy |
4
+2
| +100% | +$1.43K | ﹤0.01% | 5403 |
|
|
2022
Q1 | $2K | Buy |
2
+1
| +100% | +$846 | ﹤0.01% | 5597 |
|
|
2021
Q4 | $1K | Buy |
+1
| New | +$1.44K | ﹤0.01% | 5886 |
|
|
2021
Q2 | – | Hold |
0
| – | -$1K | – | 5818 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 5213 |
|
|
2020
Q4 | – | Sell |
-1
| Closed | -$7K | – | 5390 |
|
|
2020
Q3 | $7K | Sell |
1
-1
| -50% | -$7.21K | ﹤0.01% | 4250 |
|
|
2020
Q2 | $16K | Buy |
+2
| New | +$23.3K | ﹤0.01% | 3793 |
|
|
2015
Q1 | – | Hold |
0
| – | -$1K | – | 4885 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 3713 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 4147 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3455 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3902 |
|
|
2013
Q3 | – | Hold |
0
| – | -$18K | – | 4823 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 1824 |
|
Other funds holding SONN
Tower Research Capital (TRC)'s SONN Position: Q4 2025 in Review
Tower Research Capital (TRC) sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 1,051 shares — an estimated $4.81K sold.
Tower Research Capital (TRC) first reported a position in SONN in Q2 2020 and held it in 17 quarters. The position peaked at $16K in Q2 2020. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Tower Research Capital (TRC) reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,051 Sonnet BioTherapeutics shares in Q4 2025, an estimated $4.81K.
- Tower Research Capital (TRC) first reported a position in Sonnet BioTherapeutics in Q2 2020 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Sonnet BioTherapeutics position peaked at $16K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.